Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Modèle de glucose chez les femmes infertiles recevant une reproduction assistée à l'aide d'une surveillance continue du glucose

17 novembre 2026 mis à jour par: Jian Zhou, Shanghai 6th People's Hospital

Modèle de glucose chez les femmes infertiles recevant une reproduction assistée: une étude prospective utilisant une surveillance continue du glucose

No studies have been seen on glucose variation during medication for assisted reproduction. The aim of this study is to continuously observe glucose variation during assisted reproduction treatment using continuous glucose monitoring (CGM), and to further explore whether glucose variation will affect the outcomes related to assisted reproduction.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Description détaillée

Infertility is a growing global health concern and affects approximately 20% of couples of reproductive age. As a result, the use of assisted reproductive technologies (ART) is becoming more prevalent. This study could serve as a basis for the interpretation of glucose levels with respect to these people undergoing ART regimen. Moreover, the success rate of ART still needs to be further improved. Key challenges include optimizing the hormonal components of ART regimens and determining the ideal treatment duration. This study might provide insights into the potential benefits of monitoring glucose levels at specific points during ART cycles (which is not usually performed in routine practice) and help clinicians tailor ART regimen to minimize glucose variation, ultimately improving clinical pregnancy and live birth rates. Additionally, the findings might support integrating CGM into the clinical practice of ART, enhancing individualized patient care.

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200233
        • Shanghai Sixth People's Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 40 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  1. Informed consent and voluntary participation in this study;
  2. Age ≥ 18 years and ≤40 years old;
  3. Infertile patients who will undergo their first or second cycle of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the study center;
  4. The chosen ovulation promotion regimens is the GnRH antagonist regimen/progesterone-promoting ovulation under hyperprogesterone state (PPOS) regimen.

Exclusion Criteria:

  1. Recent infections (excluding viral infections of the reproductive system such as HPV);
  2. Recent glucocorticoid treatment or chemotherapy;
  3. Clinical conditions affecting the outcome of assisted reproduction, including repeated implantation failure, recurrent spontaneous abortion, history of unilateral oophorectomy, uterine malformations, and parental karyotype abnormalities;
  4. Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: wearing continuous glucose monitorings

Patients will wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA) to ensure continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation.

Each patient will participate in the group only once and wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA), which record glucose readings for up to 14 days.

Following the initial consultation and before initiating the ovulation induction protocol, the first CGM sensor will be placed to collect baseline data. Upon entering the ovulation induction cycle, patients will return to the hospital on the 2nd or 3rd day of menstruation, at which point the first CGM sensor will be removed, and the second sensor will be applied. This second sensor will be removed after 14 days.

In summary, this protocol ensures continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Mean sensor glucose (MSG)
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

Mean of daily continuous 24-h blood glucose

Through study completion (during assisted reproductive treatment period,about 2 months)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
time in tight range(3.9~7.8mmol/L, %)
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

Percentage of time within glucose level of 3.9-7.8 mmol/L (70-140 mg/dL) measured by CGM

Through study completion (during assisted reproductive treatment period,about 2 months)
Time below range (<3.9mmol/L, %)
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

Percentage of time below glucose level of 3.9 mmol/L (70 mg/dL) measured by CGM.

Through study completion (during assisted reproductive treatment period,about 2 months)
Time above range (>7.8mmol/L, %)
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

Percentage of time above glucose level of 7.8 mmol/L (140 mg/dL) measured by CGM

Through study completion (during assisted reproductive treatment period,about 2 months)
Coefficient of variation (CV)
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

Standard deviation divided by mean glucose level measured by CGM

Through study completion (during assisted reproductive treatment period,about 2 months)
Standard deviation (SD)
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

Standard deviation of blood glucose measurements during CGM

Through study completion (during assisted reproductive treatment period,about 2 months)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Number of oocytes retrieved
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

The number of oocytes obtained under ultrasound guidance

Through study completion (during assisted reproductive treatment period,about 2 months)
Oocyte retrieval rate
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

Oocyte Retrieval Rate = Number of Oocytes Retrieved / Number of Follicles

Through study completion (during assisted reproductive treatment period,about 2 months)
Number of MII oocytes
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

The number of metaphase II oocytes that have nuclear maturity at the time of injection

Through study completion (during assisted reproductive treatment period,about 2 months)
Rate of MII oocytes
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

the proportion of oocytes that have nuclear maturity at the time of injection

Through study completion (during assisted reproductive treatment period,about 2 months)
Rate of high-quality embryos
Délai: Through study completion (during assisted reproductive treatment period,about 2 months)

the proportion of Day 2 and Day 3 embryos with high score or grade

Through study completion (during assisted reproductive treatment period,about 2 months)
Biochemical pregnancy rate
Délai: Through study completion (during assisted reproductive treatment period,about 6 months)

The proportion of pregnancies confirmed by the detection of hCG in serum or urine, but without ultrasound confirmation of a gestational sac or fetal heartbeat.

Through study completion (during assisted reproductive treatment period,about 6 months)
Clinical pregnancy rate
Délai: Through study completion (during assisted reproductive treatment period,about 6 months)

The proportion of pregnancies confirmed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy

Through study completion (during assisted reproductive treatment period,about 6 months)
Miscarriage rate
Délai: Through study completion, about 1 year

The proportion of pregnancies that end spontaneously before 28 weeks of gestation after confirmation of clinical pregnancy

Through study completion, about 1 year
Live Birth Rate
Délai: Through study completion, 18 months

The proportion of successful deliveries resulting in a live-born infant.

Through study completion, 18 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 mars 2025

Achèvement primaire (Réel)

30 juin 2026

Achèvement de l'étude (Estimé)

30 avril 2027

Dates d'inscription aux études

Première soumission

3 mars 2025

Première soumission répondant aux critères de contrôle qualité

6 mars 2025

Première publication (Réel)

7 mars 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner